Genetic counseling is advised for people with a family history of the disorder.<unk>  can be detected with about 95% accuracy by genetic studies performed during pregnancy. Creatine kinase (CPK-MM) levels in the bloodstream are extremely high. An electromyography (EMG) shows that weakness is caused by destruction of muscle tissue rather than by damage to nerves. DNA test The muscle-specific isoform of the dystrophin gene is composed of 79 exons, and DNA testing (blood test) and analysis can usually identify the specific type of mutation of the exon or exons that are affected. DNA testing confirms the diagnosis in most cases. Muscle biopsy If DNA testing fails to find the mutation, a muscle biopsy test may be performed. A small sample of muscle tissue is extracted using a biopsy needle. The key tests performed on the biopsy sample for<unk>  are immunohistochemistry, immunocytochemistry, and immunoblotting for dystrophin, and should be interpreted by an experienced neuromuscular pathologist. These tests provide information on the presence or absence of the protein. Absence of the protein is a positive test for<unk> . Where dystrophin is present, the tests indicate the amount and molecular size of dystrophin, helping to distinguish<unk>  from milder dystrophinopathy phenotypes. Over the past several years, DNA tests have been developed that detect more of the many mutations that cause the condition, and muscle biopsy is not required as often to confirm the presence of<unk> . Prenatal tests A prenatal test can be considered when the mother is a known or suspected carrier. Prenatal tests can tell whether the unborn child has one of the most common mutations. Many mutations are responsible for<unk> , and some have not been identified, so genetic testing may be falsely negative if the suspected mutation in the mother has not been identified. Prior to invasive testing, determination of the fetal sex is important; while males are sometimes affected by this X-linked disease, female<unk>  is extremely rare. This can be achieved by ultrasound scan at 16 weeks or more recently by free fetal DNA (cffDNA) testing. Chorion villus sampling (CVS) can be done at 11–14 weeks, and has a 1% risk of miscarriage. Amniocentesis can be done after 15 weeks, and has a 0.5% risk of miscarriage. Non invasive prenatal testing can be done around 10–12 weeks. Another option in the case of unclear genetic test results is fetal muscle biopsy.
Duchenne muscular dystrophy
Limb–girdle muscular dystrophy
Becker muscular dystrophy
Brugada syndrome
Spinal muscular atrophy
Fukuyama congenital muscular dystrophy
Facioscapulohumeral muscular dystrophy
Jokela type spinal muscular atrophy